Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

nts, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Statements regarding the outcomes sought to be realized in the Phase 3 clinical trial, the possibility that otelixizumab may have the potential to change type I diabetes treatment paradigms, the anticipated progress and development of otelixizumab, in type 1 diabetes and other disease indications, are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors and risks that may impact management's expectations and affect the forward-looking statements shall include but not be limited to results of DEFEND and other future clinical studies, the ability to obtain regulatory approval for otelixizumab for type 1 diabetes or any other indication, the continuation of the collaboration with GSK, the introduction of competing therapies by other companies, and changes in the company's business plan or objectives. These statements reflect the view of Tolerx as of the date of this press release and should not be relied upon as reflecting the company's views at any date subsequent to this release. Tolerx undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... 2015  Butterfly Network was awarded today as ... Pioneers for 2015.  The company is democratizing medical ... surgery. By integrating its novel imaging platform with ... a virtuous cycle, learning as they image, and ... was chosen by a professional jury among hundreds ...
(Date:8/4/2015)... , Aug. 4, 2015 On August 3, ... held in conjunction with a donation ceremony of a million ... in Beijing . ... is a wholly-owned subsidiary of Hubei Longfeixiang Industrial Group, ... mask and the leading Baihe anti-pollution mask, filling the ...
(Date:8/4/2015)... Governor Tom Wolf announced today that ... markets implants in the spine and trauma markets, will establish ... Northampton County to serve as its ... 25 new, full-time jobs. "Tyber Medical,s decision ... more than two dozen, high-paying jobs is great news for ...
Breaking Medicine Technology:Butterfly Network Recognized as a Technology Pioneer by the World Economic Forum 2Wolf Administration Announces Tyber Medical to Establish Operations and Create New Jobs in Northampton County 2Wolf Administration Announces Tyber Medical to Establish Operations and Create New Jobs in Northampton County 3
... U.S. Food and Drug Administration (FDA) has approved BOOSTRIX® ... Adsorbed (Tdap)] for use in adults 65 years of ... diphtheria and pertussis (whooping cough). This approval makes BOOSTRIX ... age group.  With this expanded indication, BOOSTRIX is now ...
... announced yesterday that most of Kentucky,s Medicaid program would ... million. In modernizing the state,s Medicaid pharmacy benefits, the ... benefit managers (PBMs) to lower prescription drug costs, the ... "Governor Beshear has done the right thing for ...
Cached Medicine Technology:GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 2GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 3GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older 4Modernizing Medicaid Rx with 'Innovative' PBM Tools Will Help Kentucky Save $375 Million 2
(Date:8/4/2015)... , ... August 04, 2015 , ... Sponsored by Gila ... AZ, which is a 501(c) nonprofit organization. , According to the New Foundation ... Sponsors will get a package that includes a complimentary foursome for the tournament, as ...
(Date:8/4/2015)... ... August 04, 2015 , ... Exsurco Medical, Inc. ... Banks (AATB) as an Affiliate Member. Exsurco Medical finds this an exciting ... and improve lives by promoting the safety, quality and availability of donated tissue ...
(Date:8/4/2015)... ... ... Atlantic Health System, one of the largest health care organizations in New Jersey, ... their list of the 20 Best Workplaces in Health Care. , Ranked at No. ... Hospital and Atlantic Rehabilitation, is the highest-ranking company from New Jersey on the list. ...
(Date:8/4/2015)... ... ... Rhode Island Medical Imaging (RIMI) is pleased to announce the opening of ... Road in Lincoln, RI. This satellite office will provide x-ray and ultrasound exams. ... hours in the state, which includes evenings and weekends. , “This satellite office ...
(Date:8/4/2015)... ... August 04, 2015 , ... Healthy Origins® Cognizin® Citicoline ... a trademark for Citicoline, a nutrient that supports memory function and healthly cognition.* ... have more of a semi-solid composition. Vegetarian capsules are also natural, non-toxic ...
Breaking Medicine News(10 mins):Health News:The New Foundation AZ to Host Charity Golf Tournament 2Health News:The New Foundation AZ to Host Charity Golf Tournament 3Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 2Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 3Health News:Atlantic Health System Named a 'Best Workplace in Health Care' by Fortune, Great Place to Work® 4Health News:Rhode Island Medical Imaging Opens Satellite Imaging Center on Wake Robin Road in Lincoln 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3
... , , , ... researchers, and interested clinicians will each have opportunities to hear ... Alzheimer,s Disease during the Texas Brain and Spine Institute,s Third ... year,s symposium will consist of an evening of public presentations ...
... available in French . Heavy drinkers ... developing cancer than the population at large, says a group ... people in the highest consumption category increased their risk of ... lung cancer by 50%. In all, the researchers ...
... , , MINNEAPOLIS, Aug. ... center, is pleased to announce that Dianne Miron is their ... role she will direct Courage Center,s physician practice, Rehab Medicine ... Primary Care Clinic (DPCC) at Courage Center. , , ...
... , WASHINGTON, Aug. 3 The U.S. Census ... of the nation,s counties. , , (Logo: ... Small Area Health Insurance Estimates (SAHIE) are based on models ... and Economic Supplement of the Current Population Survey, Census 2000, the ...
... , , WASHINGTON, Aug. 3 ... (NPC) shows that pharmacogenomics -- the field of scientific research ... to medicines - has the potential to lead to higher ... pace of pharmaceutical innovation, offering substantial benefits for patients. ...
... PLAINSBORO, N.J., Aug. 3 Pharmacy & Healthcare ... Director of Pharmacy Times , a monthly journal that ... 112-year-old publication as well as its website, www.PharmacyTimes.com ... direct the custom supplements, including Pharmacy Times ...
Cached Medicine News:Health News:Alzheimer's Disease is the Focus of TBSI Annual Neuroscience Symposium 2Health News:Alzheimer's Disease is the Focus of TBSI Annual Neuroscience Symposium 3Health News:Heavy drinkers face significantly increased cancer risk 2Health News:Census Bureau Releases Comprehensive Health Insurance Coverage Estimates by County 2Health News:New Study Shows That Pharmacogenomics Could Benefit Patients, Spur Investment in Innovation 2Health News:New Study Shows That Pharmacogenomics Could Benefit Patients, Spur Investment in Innovation 3Health News:Pharmacy Times Names New Editorial Director 2
For the quantitative determination of high density lipoprotein (HDL) in human serum....
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl....
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
The Proteineer suite integrates powerful mass spectrometers with robotics and bioinformatics to deliver maximum productivity in high-throughput proteomics....
Medicine Products: